In the subgroup analysis of the IMpower150 trial, the KRAS-mutant NSCLC patients and co-occurring STK11 and/or KEAP1 mutations exhibited a significantly shorter median PFS of the combination therapy ABCP compared to those with wild type in both STK11 and KEAP1 (6.0 months vs. 15.2 months) (57) (Supplementary Table 2). This evidence concerns the gene KRAS and non-small cell lung carcinoma.